Direct Flow Medical is taking the next step in its attempt to show it has a better system for replacing heart valves without surgery.
The Santa Rosa company, which is competing with such medical device giants as Medtronic and Edwards Lifesciences, this month began a U.S. trial for its transcatheter aortic heart valve system. Earlier this year, the device was approved for use in Europe.
The competing systems currently are restricted to patients deemed too ill or frail for open heart surgery. The survival of these patients, many of whom are in their 80s, often depends on obtaining a new valve to control blood flow to the aorta, the main artery in the body.
Analysts estimate that the worldwide market just to serve these patients could amount to billions of dollars. Moreover, some experts foresee a time when the developing technology could become the predominant way of replacing aortic valves.
"It's new but it's incredibly promising," said Dr. William O'Neill, medical director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit.
O'Neill performed the first aortic valve replacement by catheter in the U.S. in 2005, and this month implanted the first Direct Flow valve in a U.S. patient involved in the new trial. He predicted that in a decade fewer aortic valves will be surgically replaced and that eventually "the vast majority are going to be done by these less-invasive techniques."
Direct Flow may seem a small player in this burgeoning market. The nine-year-old company has 130 employees in Santa Rosa and Lake Forest and has received $75 million in venture capital. Since it received European approval, its device has been implanted in just 130 patients there.
But its chief executive expressed confidence that what matters isn't company size but who has the most innovative product.
"Physicians want to provide their patients with the best outcomes," said Direct Flow President and CEO Bernie Lyons.